![](/img/cover-not-exists.png)
A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors
Sullivan, Ryan J., Weber, Jeffrey S., Patel, Sapna P., Dummer, Reinhard, Carlino, Matteo S., Tan, Daniel Shao-Weng, Lebbe, Celeste, Siena, Salvatore, Ãlez, Elena, Wollenberg, Lance, Pickard, Michael,Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-19-3550
Date:
July, 2020
File:
PDF, 457 KB
2020